BL-M11D1

SystImmune Inc. · Phase 2 active Small molecule

At a glance

Generic name	BL-M11D1
Sponsor	SystImmune Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (PHASE2, PHASE3)
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 (PHASE1)
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BL-M11D1 CI brief — competitive landscape report
BL-M11D1 updates RSS · CI watch RSS
SystImmune Inc. portfolio CI